Public Policy

As a biopharmaceutical company that treats serious diseases, we play an important role in public health and its related public policy debates. We believe it is important for our company to shape public policy debates around the world on issues specific to the people we serve and to our other key stakeholders, especially shareholders and employees. Our engagement in the public policy arena helps address the most pressing issues related to ensuring that patients have access to needed medications—leading to improved patient outcomes. Through public policy engagement, we provide a way for all of our locations globally to shape the policy environment in a manner that supports access to innovative medicines. We also look for ways to engage on issues specific to local business environments.

Through our policy research, development, and stakeholder dialogue activities, Lilly focuses on a number of dynamic areas that are important to our company, our industry, and the people we serve. Our public policy efforts center on three key areas: innovation; health care delivery; and pricing and reimbursement. More detailed information on key issues can be found here or in our 2012/2013 Lilly Corporate Responsibility Report.

Conflict Minerals Approach

We are concerned with the many human rights violations that occur in the Democratic Republic of Congo and the surrounding region and have adopted a policy on conflict minerals that is available as a part of our 2012/2013 Lilly Corporate Responsibility Report. We’ve also filed our 2014 Conflict Materials Report with the Securities Exchange Commission, which provides additional information on our process for identifying potential conflict minerals in our supply chain.

Political Financial Contributions

When engaging in lobbying efforts or making political contributions, we comply with the laws that govern such activities. All of our employees must also comply with our global policies, core values, and legal obligations, which are outlined in our written Code of Business Conduct, The Red Book.

Elected officials, no matter what level, have an impact on public policy issues affecting us. We lobby and make political contributions only where allowed under law.

In the United States, we are committed to backing candidates of any party who support public policies that contribute to pharmaceutical innovation and the health needs of the patient.

We are proud to have been recognized by the Center for Political Accountability as a leader in accountability and political disclosure. Our annual Report of Political Financial Support provides details of our company’s political contributions; our memberships in organizations that report lobbying activity to the U.S. government and to which we contribute $50,000 a year or more; and the activities of our Political Action Committee, the Lilly PAC, which is funded solely by employee contributions.

For more information, view the following reports:

Memberships

    In addition to direct political contributions, Lilly maintains memberships in organizations that report lobbying activity to the U.S. federal government. We support organizations that champion public policies that contribute to pharmaceutical innovation, healthy patients, and a healthy business climate.

     

    Our LillyPad blog was designed to extend a dialogue with the public on matters that are of mutual interest to us and to those following our industry. The blog focuses on public policy issues such as health and wellness, innovation, and job creation. It also describes our corporate responsibility initiatives, advocacy efforts, and the work our employees do every day to make the world a healthier place to live. Visitors may add comments to contribute to the discussion.